We are live on
!
Find out more
KCA
KVP Capital Advisors Portfolio holdings
AUM
$136M
This Fund
S&P 500
This Quarter
Est. Return
+33.24%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$30.6M
(+30%)
Cap. Flow
+$26M
Cap. Flow
% of AUM
19.42%
Top 10 Holdings %
Top 10 Hldgs %
61.06%
Holding
36
New
9
Increased
1
Reduced
–
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sutro Biopharma
STRO
|
+$4.09M |
| 2 |
Erasca
ERAS
|
+$4.02M |
| 3 |
Viridian Therapeutics
VRDN
|
+$3.71M |
| 4 |
Tango Therapeutics
TNGX
|
+$3.2M |
| 5 |
Compass Therapeutics
CMPX
|
+$2.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$2.98M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$566K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
| $23.2M | 17.32% |
440,000
| – | – |
|
2
Praxis Precision Medicines
PRAX
$9.63B
| $13.8M | 10.32% |
42,900
| – | – |
|
|
WHWK
3
Whitehawk Therapeutics
WHWK
$263M
| $7.47M | 5.58% |
2,165,997
| – | – |
|
4
Axsome Therapeutics
AXSM
$10.4B
| $6.12M | 4.57% |
36,200
| – | – |
|
|
5
Sutro Biopharma
STRO
$339M
| $5.64M | 4.22% |
+226,575
| New | +$4.09M |
|
6
Protagonist Therapeutics
PTGX
$9.34B
| $5.59M | 4.17% |
53,000
| – | – |
|
|
7
Erasca
ERAS
$6.31B
| $5.5M | 4.11% |
+340,000
| New | +$4.02M |
|
8
Trevi Therapeutics
TRVI
$2.39B
| $4.94M | 3.69% |
414,000
| – | – |
|
|
9
Tango Therapeutics
TNGX
$3.94B
| $4.82M | 3.6% |
+230,264
| New | +$3.2M |
|
10
Insmed
INSM
$25.9B
| $4.66M | 3.48% |
28,497
| – | – |
|
11
Edgewise Therapeutics
EWTX
$4.64B
| $4.19M | 3.13% |
133,000
| – | – |
|
12
Revolution Medicines
RVMD
$44.6B
| $3.91M | 2.92% |
40,200
+12,700
| +46% | +$1.28M |
|
13
Disc Medicine
IRON
$3.07B
| $3.72M | 2.78% |
58,250
| – | – |
|
|
MBX
14
MBX Biosciences
MBX
$3.03B
| $3.63M | 2.71% |
121,524
| – | – |
|
15
Savara
SVRA
$1.08B
| $3.3M | 2.47% |
605,280
| – | – |
|
16
United Therapeutics
UTHR
$22.1B
| $2.82M | 2.1% |
4,750
| – | – |
|
17
Travere Therapeutics
TVTX
$6.19B
| $2.7M | 2.02% |
91,000
| – | – |
|
18
IDEAYA Biosciences
IDYA
$3.87B
| $2.66M | 1.98% |
+79,700
| New | +$2.67M |
|
|
19
Compass Therapeutics
CMPX
$432M
| $2.65M | 1.98% |
+500,000
| New | +$2.89M |
|
20
Ocular Therapeutix
OCUL
$2.28B
| $2.54M | 1.9% |
+300,000
| New | +$2.86M |
|
|
21
Viridian Therapeutics
VRDN
$2.61B
| $2.44M | 1.83% |
+125,000
| New | +$3.71M |
|
|
DRUG
22
Bright Minds Biosciences
DRUG
$714M
| $2.32M | 1.73% |
+31,813
| New | +$2.56M |
|
23
Zura Bio
ZURA
$548M
| $2.22M | 1.66% |
+373,128
| New | +$2.25M |
|
24
Scholar Rock
SRRK
$7.04B
| $2.21M | 1.65% |
45,000
| – | – |
|
25
Immix Biopharma
IMMX
$992M
| $2.1M | 1.57% |
230,423
| – | – |
|
Similar funds
RC
TH
WFA
SB
II
FEM
SCM
VSCP
KVP Capital Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, KVP Capital Advisors held 36 positions worth $134M, up 30% from $103M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
KVP Capital Advisors deployed $26M of net new capital in Q1 2026, opening 9 new positions and adding to 1 existing holding. Its largest new stake was Sutro Biopharma: 226,575 shares worth $5.64M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.
On the sell side, the most notable exit was Jazz Pharmaceuticals, an estimated $2.98M sold.
- KVP Capital Advisors's largest Q1 2026 buy was Sutro Biopharma: 226,575 shares worth $5.64M.
- KVP Capital Advisors added most to Revolution Medicines in Q1 2026, an estimated $1.28M increase.
- KVP Capital Advisors fully exited Jazz Pharmaceuticals in Q1 2026, selling an estimated $2.98M.
- KVP Capital Advisors's ten largest holdings make up 61% of its $134M portfolio in Q1 2026.
- KVP Capital Advisors opened 9 new positions and closed 4 in Q1 2026.
- KVP Capital Advisors's portfolio value rose 30% quarter-over-quarter to $134M.
Based on KVP Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.